Validated high-conviction buyer — this insider’s opportunistic purchases fall in a cohort whose buys have historically preceded above-benchmark moves. How we measure this ↗
Director Bisaro Paul buys 7,500 shares of MYGN at $3.685 on 2026-05-14; stock down 26.3% in 30 days.
Bisaro Paul, a director, purchased 7,500 shares at $3.685, bringing his post-transaction holdings to 97,441 shares. The purchase occurred as the stock traded at $3.62 on the filing date, down 26.3% over the prior 30 days and 19.4% over 90 days from a 52-week high of $8.59. MYRIAD GENETICS remains unprofitable with net income of $-34.1M in the latest quarter despite quarterly revenue of $200.4M, and the company faces headwinds including annual revenue decline of -1.6%. The timing of this insider buy coincides with significant recent price weakness, though the available data does not indicate the director's specific motivations or investment thesis.
Director Bisaro Paul makes first open-market purchase of 2,000 shares as ZTS trades well below 52-week highs; part of 3-insider buying cluster in 14 days.
Director Bisaro Paul purchased 2,000 shares at the market, marking his first open-market purchase in the 36-month record — prior activity consisted entirely of stock-based compensation transactions. The purchase occurred as Zoetis trades substantially below its 52-week high and has declined significantly over the past quarter, but the company remains profitable with stable revenue growth and a reasonable valuation multiple. Notably, this purchase is part of a cluster of insider buying activity: three insiders acquired shares within a 14-day window, suggesting interest in the stock at current levels. Paul's decision to commit personal capital at a time when the stock faces headwinds distinguishes this from his typical compensation-driven filings.
